Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
Prescribing Information
For details of the enhanced Pregnancy Prevention Programme, please click on the prescribing information links below.
PHESGO Expert Exchange is a promotional video series produced by Roche in collaboration with Breast Oncologists. Designed to bring expert’s insights on trial data and PHESGO in clinical practice with real world patients case studies. Watch the videos below to hear Oncologists Dr Mukesh & Dr Okines discuss PHESGO and its impact on UK clinical practice. Always refer to the PHESGO Summary of Product Characteristics (UK) before treating a patient.
Explore resources
If viewing on mobile, for best viewing experience please rotate your phone to landscape mode.
Hear a real-world case study from your peers on the management of nodal involvement post-surgery in HER2+ early breast cancer with PHESGO in the adjuvant setting.
If viewing on mobile, for best viewing experience please rotate your phone to landscape mode.
Listen to Dr Okines & Dr Mukesh discuss PHESGO treatment principles and key trial data for pertuzumab/trastuzumab, including the Final Overall Survival Analysis of the APHINITY trial.
Abbreviations: N+: node-positive; eBC: early breast cancer; HER2: human epidermal growth factor receptor 2
Early breast cancer (eBC)
PHESGO is indicated for use in combination with chemotherapy in:
the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence1
the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence1
The Experts
PHESGO is a fixed-dose combination of pertuzumab and trastuzumab in one vial for subcutaneous use given every 3 weeks1
In patients receiving a taxane, PHESGO should be administered prior to the taxane.
* Patients should be observed for injection-related reactions and hypersensitivity reactions. Observation period should start following administration of PHESGO and be completed prior to any subsequent administration of chemotherapy1
Once pertuzumab-based therapy has been safely established, the physician may determine the suitability of administration of PHESGO outside of the clinical setting (e.g., at home) by a healthcare professional (see SmPC section 4.4).1
Prefer to talk things through? We’re here to speak with you about supporting your HER2+ eBC patients
Connect with our team
Reference:
- PHESGO Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11989/smpc